A Study of the Biological Characteristics of Lupus

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 15-008117
    Sponsor Protocol Number: 15-008117

About this study

The purpose of this study is to understand the characteristics associated with lupus, to assist the early development of new treatments for human lupus and Sjögren's syndrome.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Potential Participants with Systemic lupus erythematosus (SLE)

Inclusions Criteria

  • Meets definition of SLE diagnosis
  • Age 18-70
  • Meets 4 or more ACR formal diagnostic criteria
  • Anti-dsDNA positive

Exclusion Criteria

  • Age <18
  • Has chronic infectious disease
  • Has cancer and is on chemotherapy
  • CNS lupus
  • Drug-induced lupus
  • Is on IV steroids or cyclophosphamide
  • Pregnant

 

Potential Participants with Sjogren’s Syndrome (SjS)

Inclusions Criteria

  • Age 18-70
  • Meets American-European Consensus Group classification for primary Sjogren’s Syndrome
  • Previously established diagnosis of SjS and no other autoimmune connective tissue disease
  • Positive dry eye signs and symptoms, subjective dry mouth symptoms
  • Positive test for anti-Ro/SSA and/or anti-La/SSB

Exclusion Criteria

  • Age <18
  • Has chronic infectious disease,
  • Has cancer and on chemotherapy
  • Is on IV steroids or cyclophosphamide
  • Pregnant

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mark Jensen, Ph.D.

Open for enrollment

Contact information:

Danielle Vsetecka

(507)538-4826

Vsetecka.Danielle@mayo.edu